A Few Words on LFB's Pipeline

New treatments for serious and often rare diseases

LFB develops biomedicinal products within its areas of expertise namely Immunology, Hemostasis and Intensive Care, for the treatment of serious and often rare diseases.

LFB USA’s role developing new biotherapies in the US

LFB USA has a key role in developing LFB's pipeline in the US, focusing on research, clinical development and regulatory strategies and filings. For the Factor FVIIa (LR769) program, LFB USA handles the upstream manufacture of the protein and the clinical and regulatory aspects.  On April 1st, 2020, LFB's recombinant form of human Factor VIIa was recently approved by the FDA for treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with hemophilia A or B with inhibitors (neutralizing antibodies) (https://www.fda.gov/news-events/press-announcements/fda-approves-additional-treatment-adults-and-adolescents-hemophilia-or-b-and-inhibitors).  The Phase III studies in pediatric and surgical patients are now complete and will be filed soon to the FDA for review/approval for these follow-on indications.  For more information on Factor VIIa, please visit the Sevenfact®website.

LFB USA is to play a role in the clinical and regulatory development of other high-potential LFB products in the US such as: fibrinogen and liquid 10% immunoglobulin. All of these products will undergo advanced clinical and regulatory development in the US through LFB USA, as they are all currently marketed, filed or in phase II/III clinical trials in Europe and other parts of the world.

Fibrinogen Deficiency and Clottafact®
Fibrinogen deficiency (also known as Factor I deficiency) is a rare bleeding disorder caused by absent or defective Factor I blood clotting protein. The deficiency can be congenital (hypo-, dys- or afibrinogenemia) or an acquired hypofibrinogenemia (such as postpartum haemorrhage, trauma or surgical interventions including cardiovascular or digestive operations and hepatic transplantations).

Clottafact® is human plasma-derived factor I concentrate. It is used for congenital and acquired hypofibrinogenemia.

Immune Disorders and IVIG
In immune deficient patients who have decreased or inactive antibody production capabilities, IVIG is used as a plasma protein replacement therapy (IgG). It is administered to maintain adequate antibody levels to prevent infections. In patients with autoimmune disease, high dose IVIG may decrease the severity of the autoimmune diseases.

IVIG is a blood product that contains the pooled, polyvalent, IgG antibodies extracted from the plasma of blood donors. It is administered intravenously.